Isabelle Riviere
Overview
Explore the profile of Isabelle Riviere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
11393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahid S, Prockop S, Flynn G, Mauguen A, White C, Bieler J, et al.
Blood Adv
. 2025 Feb;
PMID: 39908482
Despite clinical benefit with the use of CAR T-cells, the need to manufacture patient-specific products severely limits the clinical utility of this therapy. To overcome this barrier, we developed an...
2.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
J Clin Oncol
. 2025 Jan;
:JCO2402424.
PMID: 39883889
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that...
3.
Jurgens E, Firestone R, Chaudhari J, Hosszu K, Devlin S, Shah U, et al.
J Clin Oncol
. 2024 Dec;
43(5):498-504.
PMID: 39631041
MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical...
4.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
Res Sq
. 2024 Jul;
PMID: 39011120
We designed a CD19-targeted CAR comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3z and 4-1BB/CD3z CARs. Here we report the first-in-human, phase 1 clinical...
5.
Zakrzewski J, Suh D, Markley J, Smith O, King C, Goldberg G, et al.
Nat Biotechnol
. 2024 Mar;
42(4):674.
PMID: 38531977
No abstract available.
6.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2024 Feb;
8(11):1500.
PMID: 38347164
No abstract available.
7.
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, et al.
Cancer Cell
. 2023 Oct;
41(11):1871-1891.e6.
PMID: 37802054
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor (CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic stem/progenitor cells (HSPCs). Here we expound...
8.
Park J, Nath K, Devlin S, Sauter C, Palomba M, Shah G, et al.
Nat Med
. 2023 Jul;
29(7):1710-1717.
PMID: 37400640
In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy. We initiated a phase 2...
9.
Hamieh M, Mansilla-Soto J, Riviere I, Sadelain M
Cancer Discov
. 2023 Mar;
13(4):829-843.
PMID: 36961206
Significance: Improving the clinical efficacy of CAR T cell therapies will require engineering T cells that overcome heterogeneous and low-abundance target expression while minimizing reactivity to normal tissues. Recent advances...
10.
van der Stegen S, Riviere I
Cell Stem Cell
. 2023 Mar;
30(3):248-249.
PMID: 36868193
The generation of off-the-shelf CAR-T cells from TiPSCs has been hindered by the difficulty to recapitulate adaptive T cell development and lower therapeutic efficacy compared to peripheral blood CAR-T cells....